NF-κB Comes Home  by Amin, Rupesh H. & Schlissel, Mark S.
Previews
401Immunity, Vol. 22, April, 2005, Copyright ©2005 by Elsevier Inc. DOI 10.1016/j.immuni.2005.04.002NF-B Comes Home
NF-B was discovered because of its binding to the
Igk locus intronic enhancer, but deletion of its binding
site does not appear to affect V-to-J rearrangement.
New work by Verkoczy et al. (2005) in this issue of
Immunity suggests that NF-B regulates Igk rearrange-
ment after all, by activating RAG expression during
receptor editing.
Although V(D)J recombination allows for the formation
of a near-limitless repertoire of antigen receptor mole-
cules, it frequently generates receptors with self-speci-
ficity (Wardemann et al., 2003). The potential for self-
reactivity is tested at the immature (IgM+IgD−) stage of
bone marrow B cell development. Antigen encounter at
this stage leads to rapid removal of the offending re-
ceptor from the cell surface and continued RAG gene
expression and Ig light-chain gene rearrangement until
an innocuous receptor capable of promoting develop-
ment is made (Nemazee and Weigert, 2000). Cells that
fail to produce a “good” receptor are either deleted or
anergized. This editing process ensures that self-
reactive B cells do not survive to maturity, thus prevent-
ing autoimmunity. Analysis of various knockout and
BCR transgenic mice have revealed the importance of
the B cell receptor signaling complex and signal
strength in mediating developmental progression, the
induction of editing, or cell death (Diamant et al., 2005).
Both strong signaling in response to BCR crosslinking
or weak signaling due to poor heavy- and light-chain
pairing and reduced BCR cell surface expression acti-
vate receptor editing. Downstream effectors of imma-
ture BCR signaling—namely the transcription factors
involved in continued RAG expression and gene re-
arrangement—remain largely unknown, however. Now,
in this issue of Immunity, Verkoczy et al. (2005) show
that NF-κB proteins are involved in upregulation of
RAG1 and RAG2 transcription in cells undergoing re-
ceptor editing.
Direct involvement of NF-κB in regulating V(D)J re-
combination completes an arc of investigation begun
nearly 20 years ago. NF-κB was first discovered based
on its ability to bind to κB sites within the Igk intronic
enhancer (Sen and Baltimore, 1986). Subsequently, NF-
κB’s involvement in gene regulation was shown to be
much more ubiquitous, playing key roles in develop-
mental, proinflammatory, and cell survival pathways in
most metazoan organisms. NF-κB homo- or hetero-
dimers made up p50, p52, p65 (RelA), RelB, or c-Rel
are retained in the cytoplasm by association with inhibi-
tor of NF-κB (IκB) proteins (Hayden and Ghosh, 2004).
Phosphorylation of IκB by IκB kinase (IKK) results in its
degradation and translocation of NF-κB into the nu-cleus, where it binds to cognate κB sites within the en-
hancers or promoters of target genes, thereby affecting
transcription. Previous work related to NF-κB in the im-
mune system has focused on its role in innate immunity
and antigen-receptor signaling. The new work brings
NF-κB back into the realm of early lymphoid develop-
ment and antigen receptor gene assembly. Verkoczy et
al. (2005) found that the increase in RAG mRNA levels
seen in immature B cells after BCR crosslinking was
due to an increased rate of transcription rather than
alterations in mRNA processing or stability. Moreover,
when immature cells were treated with the protein syn-
thesis inhibitor cyclohexamide, they found a similar in-
crease in RAG mRNA levels. This pointed toward a
short-lived inhibitory protein as a control point in this
pathway. IκB, the protein that retains NF-κB complexes
in the cytoplasm, is known to have an extremely short
half-life and is regulated mainly at the level of protein
stability. Treatment of cells with various inhibitors of
NF-κB activation blocked cyclohexamide or anti-BCR-
induced RAG mRNA upregulation, thus confirming the
role of NF-κB. EMSA analysis of κB binding proteins in
nuclear extracts showed that increased RAG transcrip-
tion was correlated with higher nuclear levels of p65
and c-Rel relative to p50, and chromatin immunopreci-
pitation studies demonstrated direct binding of NF-κB
complexes to RAG locus enhancers. Because p65 and
c-Rel contain transactivation domains, whereas p50
does not, the authors contend the system operates by
replacing inhibitory p50 homodimers with complexes
containing p65 or c-Rel. Accordingly, they found that
immature B cells from p50−/− mice have a higher basal
level of RAG mRNA and a hyperediting phenotype, with
increased levels of both κ light chain and κ RS re-
arrangement.
At a superficial level, these data seem in conflict with
new evidence showing that loss of tonic BCR signaling
at the immature stage leads to upregulation of RAG
gene expression and receptor editing along with other
transcriptional changes consistent with de-differentia-
tion to a pre-B cell like state (Tze et al., 2005). Interest-
ingly, that report also shows that transcript levels of
IkBa, a known direct target of NF-κB, increases upon
loss of BCR signaling. How is it that both BCR cross-
linking, which activates signaling cascades, and loss
of tonic BCR signaling result in increased editing? One
possible explanation is that antigen encounter by im-
mature B cells causes rapid receptor internalization
and subsequent loss of tonic BCR signaling, and this
in turn activates NF-κB nuclear translocation or causes
a change in the subunit composition of nuclear NF-κB
complexes. This would also explain why mutations that
decrease BCR signal strength increase receptor editing
(Diamant et al., 2005). The exact pathway by which re-
ceptor engagement and internalization might lead to
NF-κB activation in immature B cells remains to be dis-
covered. Because NF-κB is also downstream of BCR
signaling in mature B cells, other transcription factors
must become limiting for RAG transcription in later
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Dlocus transcription in these cells.
Another important result from the Verkoczy paper is D
Uthat the RAGs appear to be limiting for receptor editing.
In a transgenic anti-self BCR system, RAG1+/− mice 4
Bshowed significantly reduced editing compared to
RAG1+/+ mice. This indicates that the Igk and possibly
Igl loci are constitutively accessible to the recombina-
tion machinery in immature B cells, thereby making S
RAGs limiting in the editing reaction. Indeed a recent
Apublication from the same laboratory reaches an iden-
Jtical conclusion in mice with a polyclonal population of
DB cells (Aït-Azzouzene et al., 2005). How allelic exclu-
3sion is enforced in a system with such a high rate of
Hrecombination remains a mystery.
INF-κB was discovered because of its ability to bind
1to the κ intronic enhancer, and based on correlations
Nbetween its activation and increased V-to-Jκ rearrange-
ment in transformed pre-B cell lines, it was initially S
thought to be a controlling factor in recombination of S
that locus (Schlissel and Baltimore, 1989). A recent re- T
port has shown that mutation of the κB element within J
the enhancer appears to have no effect on k locus re- (
combination (although that report did not assess the V
necessity of the κB binding site in an editing context) D
5(Inlay et al., 2004). Yet as Verkoczy et al. (2005) demon-
strate, it was premature to rule out NF-κB as a critical W
aregulator of light-chain gene rearrangement.upesh H. Amin and Mark S. Schlissel
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